Developing microbiome-derived therapeutics targeting Fusobacterium nucleatum-induced chemoresistance in colorectal cancer. Our lead candidate also addresses chemo-induced GI toxicity. Two unmet needs, one mechanistic platform.
A defined, scalable biologic.
In colorectal cancer, Fusobacterium nucleatum colonizes the tumor microenvironment and drives resistance to chemotherapy, blocking treatment response and worsening patient outcomes.
Patients with high F. nucleatum burden face significantly reduced survival, yet no approved therapeutic targets this mechanism.